Regulatory Innovation: A Dialogue
This article was originally published in RPM Report
Executive Summary
Center for Drug Evaluation & Research Deputy Director Douglas Throckmorton and AstraZeneca R&D President Martin Mackay took part in a moderated discussion of new initiatives and ideas for drug regulation during The RPM Report’s FDA/CMS Summit in Washington DC in December 2011. Here is a portion of that conversation, transcribed by The RPM Report and lightly edited for clarity.